Literature DB >> 15927270

Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice.

Paul A Smith1, Margaret Morris-Downes, Nicole Heijmans, Gareth Pryce, Elizabeth Arter, Janet K O'Neill, Bert 't Hart, David Baker, Sandra Amor.   

Abstract

Emerging autoimmunity (epitope-spreading) generated as a consequence of myelin damage is suggested to underlie the relapses in multiple sclerosis (MS). Myelin oligodendrocyte glycoprotein (MOG 8-21) induces relapsing EAE in ABH mice characterized by broadening of the autoimmune reportoire. Despite epitope spreading tolerance to the priming antigen, but not emerging epitope reactivities, resulted in long-term inhibition of clinical relapse. In contrast, spinal cord homogenate induced EAE was dominated by a proteolipid protein (PLP 56-70) autoreactivity despite the plethora of CNS antigens in the immunogen. This data suggests that during relapsing-remitting demyelinating disease the pathogenic process is dominated by the initiating antigen, with only a minor role played by emerging T-cell populations. These findings may have important implications for the efficacy of antigen-based immune therapies in autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927270     DOI: 10.1016/j.jneuroim.2005.04.006

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Authors:  Anna E Kersh; Lindsay J Edwards; Brian D Evavold
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

2.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

Review 3.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

4.  Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis.

Authors:  Fabiola Puentes; Baukje J van der Star; Marion Victor; Markus Kipp; Cordian Beyer; Regina Peferoen-Baert; Kimberley Ummenthum; Gareth Pryce; Wouter Gerritsen; Ruth Huizinga; Arie Reijerkerk; Paul van der Valk; David Baker; Sandra Amor
Journal:  J Neuroinflammation       Date:  2013-09-22       Impact factor: 8.322

5.  Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.

Authors:  Stephanie von Kutzleben; Gareth Pryce; Gavin Giovannoni; David Baker
Journal:  Immunology       Date:  2017-01-03       Impact factor: 7.397

6.  Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.

Authors:  David W Hampton; Andrea Serio; Gareth Pryce; Sarah Al-Izki; Robin Jm Franklin; Gavin Giovannoni; David Baker; Siddharthan Chandran
Journal:  Acta Neuropathol Commun       Date:  2013-12-23       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.